Elan leans on ISEQ losers
Shares at pharmaceutical company Elan tumbled 6% today after sales of its multiple sclerosis drug Tysabri came below expectations.
The stock led ISEQ-listed fallers with an overall decline of 92.61points at 9608.8.
Elan reported wider pre-tax losses of $92m (€67.8m) for the first three months of this year. This compares with $32m (€23.6m) in the same period last year.
The company blamed the increased losses on a charge related to the repayment of some of its debt.
Anglo Irish Bank led the financial heavyweights on their early morning downward spiral with a loss of 20c at €16.46.
IL&P fell 11c to €20.63, AIB 10c at €22.78 and Bank of Ireland was also down, losing 8c at €16.28.
